This outcome correlated with the outcome of work by several groups, which revealed that anti-CEACAM6 antibodies would inhibit the migration, invasive nature of tumor cells and adhesion through the interference of homo/hetero-typic binding which in turn invalidated the anoikis resistance (anchorage independent growth) of lung adenocarcinoma [40,42,43], while inhibiting the cellular proliferation, migration and invasive nature of triple negative breast cancer via the SRC and AKT signaling pathways [40,44]. This evidence concerns the gene SRC and triple-negative breast carcinoma.